18 2018年版腫瘤診療規(guī)范 腦膠質(zhì)瘤診療規(guī)范

參考文獻(xiàn)中國腦膠質(zhì)瘤協(xié)作組.中國腦膠質(zhì)瘤分子診療指南.中華神經(jīng)外科雜志gliomas:responseassessmentinneuro-oncologyworkinggroup.JClinOncol2010;28:1963-1972.BrandesAA,TosoniA,FranceschiE,etal.Recurrencepatternaftertemozolomideconcomitantwithandadjuvanttoradiotherapyinnewlydiagnosedpatientswithglioblastoma:correlationWithMGMTpromotermethylationstatus.JClinOncol2009;27:1275-1279.ChenW,SilvermanDH,DelaloyeS,etal.18F-FDOPAPETimagingofbraintumors:comparisonstudywith18F-FDGPETandevaluationofdiagnosticaccuracy.JNuclMed2006;47:904-911.HerrmannK,CzerninJ,CloughesyT,etal.Comparisonofvisualandsemiquantitativeanalysisof18F-FDOPA-PET/CTforrecurrencedetectioninglioblastomapatients.Neuro-oncology2014;16:603-609.WalterF,CloughesyT,WalterMA,etal.Impactof3,4-dihydroxy-6-18F-fluoro-L-phenylalaninePET/CTonmanagingpatientswithbraintumors:thereferringphysician'sperspective.JNuclMed2012;53:393-398.AlbertNL,WellerM,SuchorskaB,etal.ResponseAssessmentinNeuro-OncologyworkinggroupandEuropeanAssociationforNeuro-OncologyrecommendationsfortheclinicaluseofPETimagingingliomas.Neuro-oncology2016;18:1199-1208.VogesJ,HerholzK,HolzerT,etal.11C-methionineand18F-2-fluorodeoxyglucosepositronemissiontomography:atoolfordiagnosisofcerebralgliomaandmonitoringafterbrachytherapywith125Iseeds.StereotactFunctNeurosurg1997;69:129-135.WyssM,HoferS,BruehlmeierM,etal.Earlymetabolicresponsesintemozolomidetreatedlow-gradegliomapatients.Journalofneuro-oncology2009;95:87-93.SinghD,ChanJM,ZoppoliP,etal.TransformingfusionsofFGFRandTACCgenesinhumanglioblastoma.Science2012;337:1231-1235.ZhangW,ZhangJ,HoadleyK,etal.miR-181d:apredictiveglioblastomabiomarkerthatdownregulatesMGMTexpression.Neuro-oncology2012;14:712-719.BaoZS,ChenHM,YangMY,etal.RNA-seqof272gliomasrevealedanovel,recurrentPTPRZ1-METfusiontranscriptinsecondaryglioblastomas.Genomeresearch2014;24:1765-1773.WuJS,ZhouLF,TangWJ,etal.Clinicalevaluationandfollow-upoutcomeofdiffusiontensorimaging-basedfunctionalneuronavigation:aprospective,controlledstudyinpatientswithgliomasinvolvingpyramidaltracts.Neurosurgery2007;61:935-948;discussion948-939.DuffauH.Issupratotalresectionofglioblastomainnoneloquentareaspossible?Worldneurosurgery2014;82:e101-103.WuJS,GongX,SongYY,etal.3.0-Tintraoperativemagneticresonanceimaging-guidedresectionincerebralgliomasurgery:interimanalysisofaprospective,randomized,triple-blind,parallel-controlledtrial.Neurosurgery2014;61Suppl1:145-154.KumarA,ChandraPS,SharmaBS,etal.Theroleofneuronavigation-guidedfunctionalMRIanddiffusiontensortractographyalongwithcorticalstimulationinpatientswitheloquentcortexlesions.BrJNeurosurg2014;28:226-233.BelloL,GambiniA,CastellanoA,etal.MotorandlanguageDTIFiberTrackingcombinedwithintraoperativesubcorticalmappingforsurgicalremovalofgliomas.NeuroImage2008;39:369-382.StummerW,PichlmeierU,MeinelT,etal.Fluorescence-guidedsurgerywith5-aminolevulinicacidforresectionofmalignantglioma:arandomisedcontrolledmulticentrephaseIIItrial.LancetOncol2006;7:392-401.PignattiF,vandenBentM,CurranD,etal.Prognosticfactorsforsurvivalinadultpatientswithcerebrallow-gradeglioma.JClinOncol2002;20:2076-2084.AhmadiR,DictusC,HartmannC,etal.Long-termoutcomeandsurvivalofsurgicallytreatedsupratentoriallow-gradegliomainadultpatients.ActaNeurochir(Wien)2009;151:1359-1365.IusT,IsolaM,BudaiR,etal.Low-gradegliomasurgeryineloquentareas:volumetric.中國腦膠質(zhì)瘤協(xié)作組成人幕上低級別膠質(zhì)瘤的手術(shù)治療指南中華神經(jīng)外科雜志.張忠,江濤,謝堅(jiān)術(shù)中功能定位切除輔助運(yùn)動區(qū)低級別膠質(zhì)瘤.張忠,江濤,謝堅(jiān)喚醒麻醉和術(shù)中功能定位切除語言區(qū)膠質(zhì)瘤中華神經(jīng)外科雜志中華神經(jīng)外科雜志白.紅民,江濤,王偉民類別特異性命名區(qū)腦定位的臨床研究中華神經(jīng)外科雜志66中.國腦膠質(zhì)瘤協(xié)作組.喚醒狀態(tài)下切除腦功能區(qū)膠質(zhì)瘤手術(shù)技術(shù)指南（201版4）.中國微侵襲神經(jīng)外科雜志2014;19:479-485.吳勁松毛穎姚成軍術(shù)中磁共振影像神經(jīng)導(dǎo)航治療腦膠質(zhì)瘤的臨床初步應(yīng)用附例分析）.中國微侵襲神經(jīng)外科雜志2007;12:105-109.IlmbergerJ,RugeM,KrethFW,etal.Intraoperativemappingoflanguagefunctions:alongitudinalneurolinguisticanalysis.JNeurosurg2008;109:583-592.DuffauH,CapelleL,SichezN,etal.Intraoperativemappingofthesubcorticallanguagepathwaysusingdirectstimulations.Ananatomo-functionalstudy.Brain2002;125:199-214.MagillST,HanSJ,LiJ,etal.Resectionofprimarymotorcortextumors:feasibilityandsurgicaloutcomes.Journalofneurosurgery2017:1-12.SanaiN,BergerMS.Gliomaextentofresectionanditsimpactonpatientoutcome.Neurosurgery2008;62:753-764;discussion264-756.SanaiN,BergerMS.Operativetechniquesforgliomasandthevalueofextentofresection.Neurotherapeutics2009;6:478-486.ZhangZ,JiangT,XieJ,etal.Surgicalstrategiesforgliomainvolvinglanguageareas.Chinesemedicaljournal2008;121:1800-1805.LimaGLO,DezamisE,CornsR,etal.Surgicalresectionofincidentaldiffusegliomasinvolvingeloquentbrainareas.Rationale,functional,epileptologicalandoncologicaloutcomes.Neurochirurgie2017;63:250-258.XiaL,FangC,ChenG,etal.Relationshipbetweentheextentofresectionandthesurvivalofpatientswithlow-gradegliomas:asystematicreviewandmeta-analysis.BMCCancer2018;18:48.JiangB,ChaichanaK,VeeravaguA,etal.Biopsyversusresectionforthemanagementoflow-gradegliomas.CochraneDatabaseSystRev2017;4:CD009319.EnglotDJ,HanSJ,BergerMS,etal.Extentofsurgicalresectionpredictsseizurefreedominlow-gradetemporallobebraintumors.Neurosurgery2012;70:921-928;discussion928.YouG,ShaZY,YanW,etal.Seizurecharacteristicsandoutcomesin508Chineseadultpatientsundergoingprimaryresectionoflow-gradegliomas:aclinicopathologicalstudy.Neuro-oncology2012;14:230-241.ClusmannH,KralT,GleissnerU,etal.Analysisofdifferenttypesofresectionforpediatricpatientswithtemporallobeepilepsy.Neurosurgery2004;54:847-859;discussion859-860.WangYY,ZhangT,LiSW,etal.Mappingp53mutationsinlow-gradeglioma:avoxel-basedneuroimaginganalysis.AJNRAmericanjournalofneuroradiology2015;36:70-76.ZaatrehMM,SpencerDD,ThompsonJL,etal.Frontallobetumoralepilepsy:clinical,neurophysiologicfeaturesandpredictorsofsurgicaloutcome.Epilepsia2002;43:727-733.WrayCD,McDanielSS,SanetoRP,etal.Ispostresectiveintraoperativeelectrocorticographypredictiveofseizureoutcomesinchildren?JNeurosurgPediatr2012;9:546-551.YaoPS,ZhengSF,WangF,etal.Surgeryguidedwithintraoperativeelectrocorticographyinpatientswithlow-gradegliomaandrefractoryseizures.Journalofneurosurgery2018;128:840-845.PereiraLC,OliveiraKM,L'AbbateGL,etal.Outcomeoffullyawakecraniotomyforlesionsneartheeloquentcortex:analysisofaprospectivesurgicalseriesof79supratentorialprimarybraintumorswithlongfollow-up.ActaNeurochir(Wien)2009;151:1215-1230.LimaGL,DuffauH.Isthereariskofseizuresin"preventive"awakesurgeryforincidentaldiffuselow-gradegliomas?Journalofneurosurgery2015;122:1397-1405.BoettoJ,BertramL,MoulinieG,etal.LowRateofIntraoperativeSeizuresDuringAwakeCraniotomyinaProspectiveCohortwith374SupratentorialBrainLesions:ElectrocorticographyIsNotMandatory.Worldneurosurgery2015;84:1838-1844.VechtCJ,KerkhofM,Duran-PenaA.Seizureprognosisinbraintumors:newinsightsandevidence-basedmanagement.Theoncologist2014;19:751-759.DiBonaventuraC,AlbiniM,D'EliaA,etal.Epilepticseizuresheraldingarelapseinhighgradegliomas.Seizure2017;51:157-162.KahlenbergCA,FadulCE,RobertsDW,etal.Seizureprognosisofpatientswithlow-gradetumors.Seizure2012;21:540-545.SunMZ,OhT,IvanME,etal.Survivalimpactoftimetoinitiationofchemoradiotherapyafterresectionofnewlydiagnosedglioblastoma.Journalofneurosurgery2015;122:1144-1150.MerchantTE,KunLE,WuS,etal.PhaseIItrialofconformalradiationtherapyforpediatriclow-gradeglioma.JClinOncol2009;27:3598-3604.CabreraAR,KirkpatrickJP,FiveashJB,etal.Radiationtherapyforglioblastoma:ExecutivesummaryofanAmericanSocietyforRadiationOncologyEvidence-BasedClinicalPracticeGuideline.PractRadiatOncol2016;6:217-225.NationalComprehensiveCancerNetwork.NCCNClinicalPracticeGuidelinesinOncology:CentralNervousSystemCancers(Version1.2018).2018.ChiesaS,etal.PD-0516:Edemaornotedema:thisthematteringlioblastomaCTV!HypothesisfromtwosequentialphaseIIstudies.RadiotherapyandOncology2014;111:S203-S204.GilbertMR,WangM,AldapeKD,etal.Dose-densetemozolomidefornewlydiagnosedglioblastoma:arandomizedphaseIIIclinicaltrial.JClinOncol2013;31:4085-4091.ChangEL,AkyurekS,AvalosT,etal.Evaluationofperitumoraledemainthedelineationofradiotherapyclinicaltargetvolumesforglioblastoma.IntJRadiatOncolBiolPhys2007;68:144-150.StuppR,MasonWP,vandenBentMJ,etal.Radiotherapyplusconcomitantandadjuvanttemozolomideforglioblastoma.TheNewEnglandjournalofmedicine2005;352:987-996.HegiME,DiserensAC,GorliaT,etal.MGMTgenesilencingandbenefitfromtemozolomideinglioblastoma.TheNewEnglandjournalofmedicine2005;352:997-1003.vandenBentMJ,BrandesAA,TaphoornMJ,etal.Adjuvantprocarbazine,lomustine,andvincristinechemotherapyinnewlydiagnosedanaplasticoligodendroglioma:long-termfollow-upofEORTCbraintumorgroupstudy26951.JClinOncol2013;31:344-350.CairncrossG,WangM,ShawE,etal.PhaseIIItrialofchemoradiotherapyforanaplasticoligodendroglioma:long-termresultsofRTOG9402.JClinOncol2013;31:337-343.IntergroupRadiationTherapyOncologyGroupT,CairncrossG,BerkeyB,etal.PhaseIIItrialofchemotherapyplusradiotherapycomparedwithradiotherapyaloneforpureandmixedanaplasticoligodendroglioma:IntergroupRadiationTherapyOncologyGroupTrial9402.JClinOncol2006;24:2707-2714.YangP,CaiJ,YanW,etal.ClassificationbasedonmutationsofTERTpromoterandIDHcharacterizessubtypesingradeII/IIIgliomas.Neuro-oncology2016;18:1099-1108.DanielsTB,BrownPD,FeltenSJ,etal.ValidationofEORTCprognosticfactorsforadultswithlow-gradeglioma:areportusingintergroup86-72-51.IntJRadiatOncolBiolPhys2011;81:218-224.SmithJS,PerryA,BorellTJ,etal.Alterationsofchromosomearms1pand19qaspredictorsofsurvivalinoligodendrogliomas,astrocytomas,andmixedoligoastrocytomas.JClinOncol2000;18:636-645.NaborsLB,PortnowJ,AmmiratiM,etal.NCCNGuidelinesInsights:CentralNervousSystemCancers,Version1.2017.JNatlComprCancNetw2017;15:1331-1345.ShawEG,BerkeyB,CoonsSW,etal.Recurrencefollowingneurosurgeon-determinedgross-totalresectionofadultsupratentoriallow-gradeglioma:resultsofaprospectiveclinicaltrial.Journalofneurosurgery2008;109:835-841.KarimAB,MaatB,HatlevollR,etal.Arandomizedtrialondose-responseinradiationtherapyoflow-gradecerebralglioma:EuropeanOrganizationforResearchandTreatmentofCancer126.《中國中樞神經(jīng)系統(tǒng)膠質(zhì)瘤診斷與治療指南》編寫組.中國中樞神經(jīng)系統(tǒng)膠質(zhì)瘤診斷與治療指南（20）1.5中華醫(yī)學(xué)雜志2016;96:485-509.2007;82:81-83.StuppR,HegiME,MasonWP,etal.EffectsofradiotherapywithconcomitantandadjuvanttemozolomideversusradiotherapyaloneonsurvivalinglioblastomainarandomisedphaseIIIstudy:5-yearanalysisoftheEORTC-NCICtrial.LancetOncol2009;10:459-466.WolffJE,BerrakS,KoontzWebbSE,etal.Nitrosoureaefficacyinhigh-gradeglioma:asurvivalgainanalysissummarizing504cohortswith24193patients.Journalofneuro-oncology2008;88:57-63.vandenBentMJ,BaumertB,ErridgeSC,etal.InterimresultsfromtheCATNONtrial(EORTCstudy26053-22054)oftreatmentwithconcurrentandadjuvanttemozolomidefor1p/19qnon-co-deletedanaplasticglioma:aphase3,randomised,open-labelintergroupstudy.Lancet2017;390:1645-1653.RoaW,BrasherPM,BaumanG,etal.Abbreviatedcourseofradiationtherapyinolderpatientswithglioblastomamultiforme:aprospectiverandomizedclinicaltrial.JClinOncol2004;22:1583-1588.MalmstromA,GronbergBH,MarosiC,etal.Temozolomideversusstandard6-weekradiotherapyversushypofractionatedradiotherapyinpatientsolderthan60yearswithglioblastoma:theNordicrandomised,phase3trial.LancetOncol2012;13:916-926.GornetMK,BucknerJC,MarksRS,etal.ChemotherapyforadvancedCNSependymoma.Journalofneuro-oncology1999;45:61-67.RudaR,BosaC,MagistrelloM,etal.Temozolomideassalvagetreatmentforrecurrentintracranialependymomasoftheadult:aretrospectivestudy.Neuro-oncology2016;18:261-268.ShawEG,WangM,CoonsSW,etal.Randomizedtrialofradiationtherapyplusprocarbazine,lomustine,andvincristinechemotherapyforsupratentorialadultlow-gradeglioma:initialresultsofRTOG9802.JClinOncol2012;30:3065-3070.PouratianN,GascoJ,ShermanJH,etal.Toxicityandefficacyofprotractedlowdosetemozolomideforthetreatmentoflowgradegliomas.Journalofneuro-oncology2007;82:281-288.KesariS,SchiffD,DrappatzJ,etal.PhaseIIstudyofprotracteddailytemozolomideforlow-gradegliomasinadults.ClinCancerRes2009;15:330-337.NicholsonHS,KretschmarCS,KrailoM,etal.Phase2studyoftemozolomideinchildrenandadolescentswithrecurrentcentralnervoussystemtumors:areportfromtheChildren'sOncologyGroup.Cancer2007;110:1542-1550.PerryJR,RizekP,CashmanR,etal.Temozolomiderechallengeinrecurrentmalignantgliomabyusingacontinuoustemozolomideschedule:the"rescue"approach.Cancer2008;113:2152-2157.TriebelsVH,TaphoornMJ,BrandesAA,etal.SalvagePCVchemotherapyfortemozolomide-resistantoligodendrogliomas.Neurology2004;63:904-906.MassiminoM,SpreaficoF,RivaD,etal.Alower-dose,lower-toxicitycisplatin-etoposideregimenforchildhoodprogressivelow-gradeglioma.Journalofneuro-oncology2010;100:65-71.MoghrabiA,FriedmanHS,AshleyDM,etal.PhaseIIstudyofcarboplatin(CBDCA)inprogressivelow-gradegliomas.NeurosurgFocus1998;4:e3.BrandesAA,BassoU,VastolaF,etal.Carboplatinandteniposideasthird-linechemotherapyinpatientswithrecurrentoligodendrogliomaoroligoastrocytoma:aphaseIIstudy.AnnOncol2003;14:1727-1731.YungWK,PradosMD,Yaya-TurR,etal.MulticenterphaseIItrialoftemozolomideinpatientswithanaplasticastrocytomaoranaplasticoligoastrocytomaatfirstrelapse.TemodalBrainTumorGroup.JClinOncol1999;17:2762-2771.PerryJR,BelangerK,MasonWP,etal.PhaseIItrialofcontinuousdose-intensetemozolomideinrecurrentmalignantglioma:RESCUEstudy.JClinOncol2010;28:2051-2057.WickW,PuduvalliVK,ChamberlainMC,etal.PhaseIIIstudyofenzastaurincomparedwithlomustineinthetreatmentofrecurrentintracranialglioblastoma.JClinOncol2010;28:1168-1174.NordenAD,YoungGS,SetayeshK,etal.Bevacizumabforrecurrentmalignantgliomas:efficacy,toxicity,andpatternsofrecurrence.Neurology2008;70:779-787.ChamberlainMC,JohnstonS.Bevacizumabforrecurrentalkylator-refractoryanaplasticoligodendroglioma.Cancer2009;115:1734-1743.ChamberlainMC,JohnstonS.Salvagechemotherapywithbevacizumabforrecurrentalkylator-refractoryanaplasticastrocytoma.Journalofneuro-oncology2009;91:359-367.TaillibertS,VincentLA,GrangerB,etal.Bevacizumabandirinotecanforrecurrentoligodendroglialtumors.Neurology2009;72:1601-1606.VredenburghJJ,DesjardinsA,HerndonJE,2nd,etal.PhaseIItrialofbevacizumabandirinotecaninrecurrentmalignantglioma.ClinCancerRes2007;13:1253-1259.SoffiettiRRR,TrevisanE,etal.PhaseIIstudyofbevacizumabandnitrosoureainpatientswithrecurrentmalignantglioma:AmulticenterItalianstudy[abstract].JClinOncol2009;27:2012.MrugalaMM,CrewLK,FinkJR,etal.Carboplatinandbevacizumabforrecurrentmalignantglioma.OncolLett2012;4:1082-1086.ThompsonEM,DosaE,KraemerDF,etal.Treatmentwithbevacizumabpluscarboplatinforrecurrentmalignantglioma.Neurosurgery2010;67:87-93.ChamberlainMC,Wei-TsaoDD,BlumenthalDT,etal.SalvagechemotherapywithCPT-11forrecurrenttemozolomide-refractoryanaplasticastrocytoma.Cancer2008;112:2038-2045.ChamberlainMC.SalvagechemotherapywithCPT-11forrecurrentoligodendrogliomas.Journalofneuro-oncology2002;59:157-163.ChamberlainMC,Tsao-WeiDD.Salvagechemotherapywithcyclophosphamideforrecurrent,temozolomide-refractoryglioblastomamultiforme.Cancer2004;100:1213-1220.ChamberlainMC,Tsao-WeiDD,GroshenS.Salvagechemotherapywithcyclophosphamideforrecurrenttemozolomide-refractoryanaplasticastrocytoma.Cancer2006;106:172-179.FultonD,UrtasunR,ForsythP.PhaseIIstudyofprolongedoraltherapywithetoposide(VP16)forpatientswithrecurrentmalignantglioma.Journalofneuro-oncology1996;27:149-155.FriedmanHS,PradosMD,WenPY,etal.Bevacizumabaloneandincombinationwithirinotecaninrecurrentglioblastoma.JClinOncol2009;27:4733-4740.KreislTN,KimL,MooreK,etal.PhaseIItrialofsingle-agentbevacizumabfollowedbybevacizumabplusirinotecanattumorprogressioninrecurrentglioblastoma.JClinOncol2009;27:740-745.VredenburghJJ,DesjardinsA,HerndonJE,2nd,etal.Bevacizumabplusirinotecaninrecurrentglioblastomamultiforme.JClinOncol2007;25:4722-4729.YungWK,AlbrightRE,OlsonJ,etal.AphaseIIcarbazineinpatientswithglioblastomamultiformeatfirstrelapse.BrJCancer2000;83:588-593.StuppR,TaillibertS,KannerAA,etal.MaintenanceTherapyWithTumor-TreatingFieldsPlusTemozolomidevsTemozolomideAloneforGlioblastoma:ARandomizedClinicalTrial.JAMA2015;314:2535-2543.FergusonSD,XiuJ,WeathersSP,etal.GBM-associatedmutationsandalteredproteinexpressionaremorecommoninyoungpatients.Oncotarget2016;7:69466-69478.BatchelorTT,BetenskyRA,EspositoJM,etal.Age-dependentprognosticeffectsofgeneticalterationsinglioblastoma.ClinCancerRes2004;10:228-233.VuorinenV,HinkkaS,FarkkilaM,etal.Debulkingorbiopsyofmalignantgliomainelderlypeople-arandomisedstudy.ActaNeurochir(Wien)2003;145:5-10.AlmenawerSA,BadhiwalaJH,AlhazzaniW,etal.Biopsyversuspartialversusgrosstotalresectioninolderpatientswithhigh-gradeglioma:asystematicreviewandmeta-analysis.Neuro-oncology2015;17:868-881.ExtermannM,HurriaA.Comprehensivegeriatricassessmentforolderpatientswithcancer.JClinOncol2007;25:1824-1831.VanderWaldeN,JagsiR,DotanE,etal.NCCNGuidelinesInsights:OlderAdultOncology,Version2.2016.JNatlComprCancNetw2016;14:1357-1370.PerryJR,LaperriereN,O'CallaghanCJ,etal.Short-CourseRadiationplusTemozolomideinElderlyPatientswithGlioblastoma.TheNewEnglandjournalofmedicine2017;376:1027-1037.DonaldsonSS,LaninghamF,FisherPG.Advancestowardanunderstandingofbrainstemgliomas.JClinOncol2006;24:1266-1272.RineerJ,SchreiberD,ChoiK,etal.Characterizationandoutcomesofinfratentorialmalignantglioma:apopulation-basedstudyusingtheSurveillanceEpidemiologyandEnd-Resultsdatabase.RadiotherOncol2010;95:321-326.RecinosPF,SciubbaDM,JalloGI.Brainstemtumors:wherearewetoday?PediatrNeurosurg2007;43:192-201.BechetD,GielenGG,KorshunovA,etal.Specificdetectionofmethionine27mutationinhistone3variants(H3K27M)infixedtissuef